Featured Research

from universities, journals, and other organizations

Preclinical effectiveness of TB drug target validated

Date:
December 5, 2011
Source:
SRI International
Summary:
Scientists evaluating new drug targets against tuberculosis recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

Model of inhibitor bound to gyrase B ATP-binding site.
Credit: Image courtesy of SRI International

In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

DNA gyrase is an enzyme consisting of two subunits: gyrase A and gyrase B. Although gyrase A is often the target of antibiotics, such as ciprofloxacin, there currently is no antibiotic on the market that targets gyrase B. In laboratory experiments, SRI researchers found that by targeting gyrase B, TB bacteria are killed whether they are replicating or dormant. Further studies will be conducted toward the development of a TB drug against gyrase B.

"One of the greatest needs in infectious disease treatment is a drug that allows a shorter length of treatment," said Peter Madrid, Ph.D., program director in the Center for Infectious Disease and Biodefense Research, SRI Biosciences Division. "Though our program is still in the preclinical phase of research, with a number of years of required testing ahead, our goal is to develop a drug that will improve the treatment process for TB patients."

TB patients currently undergo treatment for six months and take a combination of at least four different drugs. There are often challenges to treatment effectiveness because of the long treatment time, including low patient treatment compliance and high rates of drug resistance. Tuberculosis that is resistant to multiple drugs takes even longer to treat, usually 18 to 24 months.

Research results are presented in the November 2011 Journal of Antimicrobial Chemotherapy in a paper titled "Evaluation of Gyrase B as a Drug Target in Mycobacterium tuberculosis."

The project described was supported by Award Numbers R56AI090817 and U01AI082070 from the National Institute of Allergy And Infectious Diseases.


Story Source:

The above story is based on materials provided by SRI International. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Chopra, K. Matsuyama, T. Tran, J. P. Malerich, B. Wan, S. G. Franzblau, S. Lun, H. Guo, M. C. Maiga, W. R. Bishai, P. B. Madrid. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2011; DOI: 10.1093/jac/dkr449

Cite This Page:

SRI International. "Preclinical effectiveness of TB drug target validated." ScienceDaily. ScienceDaily, 5 December 2011. <www.sciencedaily.com/releases/2011/11/111129151544.htm>.
SRI International. (2011, December 5). Preclinical effectiveness of TB drug target validated. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2011/11/111129151544.htm
SRI International. "Preclinical effectiveness of TB drug target validated." ScienceDaily. www.sciencedaily.com/releases/2011/11/111129151544.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Obama Orders Military Response to Ebola

Obama Orders Military Response to Ebola

AP (Sep. 16, 2014) Calling the Ebola outbreak in West Africa a potential threat to global security, President Barack Obama is ordering 3,000 U.S. military personnel to the stricken region amid worries that the outbreak is spiraling out of control. (Sept. 16) Video provided by AP
Powered by NewsLook.com
UN: 20,000 Could Be Infected With Ebola by Year End

UN: 20,000 Could Be Infected With Ebola by Year End

AFP (Sep. 16, 2014) Nearly $1.0 billion dollars is needed to fight the Ebola outbreak raging in west Africa, the United Nations say, warning that 20,000 could be infected by year end. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins